Literature DB >> 9683226

Pathogenesis, prevention, and treatment of diabetic nephropathy.

M E Cooper1.   

Abstract

It is likely that the pathophysiology of diabetic nephropathy involves an interaction of metabolic and haemodynamic factors. Relevant metabolic factors include glucose-dependent pathways such as advanced glycation, increased formation of polyols, and activation of the enzyme, protein kinase C. Specific inhibitors of the various pathways are now available, enabling investigation of the role of these processes in the pathogenesis of diabetic nephropathy and potentially to provide new therapeutic approaches for the prevention and treatment of diabetic nephropathy. Haemodynamic factors to consider include systemic hypertension, intraglomerular hypertension, and the role of vasoactive hormones, such as angiotensin II. The mainstay of therapy remains attaining optimum glycaemic control. Antihypertensive therapy has a major role in slowing the progression of diabetic nephropathy. Agents that interrupt the renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists may be particularly useful as renoprotective agents in both the hypertensive and normotensive context.

Entities:  

Mesh:

Year:  1998        PMID: 9683226     DOI: 10.1016/S0140-6736(98)01346-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  108 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

3.  CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells.

Authors:  Xiaoyu Wang; Susan V McLennan; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2011-06-02       Impact factor: 5.782

Review 4.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

5.  End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.

Authors:  X L Yang; W Y So; A P S Kong; P Clarke; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

6.  Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.

Authors:  Alaa S Awad; Michael D Rouse; Konstantine Khutsishvili; Liping Huang; W Kline Bolton; Kevin R Lynch; Mark D Okusa
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

Review 7.  Angiotensin receptor blockers in diabetic nephropathy.

Authors:  D A Price; N K Hollenberg
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 8.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

9.  Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.

Authors:  Mahmut Ilker Yilmaz; Alper Sonmez; Kayser Caglar; Deniz Engin Gok; Tayfun Eyileten; Müjdat Yenicesu; Cengizhan Acikel; Necati Bingol; Selim Kilic; Yusuf Oguz; Abdulgaffar Vural
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

Review 10.  Vitamin D and diabetic nephropathy.

Authors:  Yan Chun Li
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.